Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira Pharm Inc (NQ: PCRX )

17.55 +0.17 (+0.98%)
Streaming Delayed Price Updated: 10:52 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira Pharm Inc

< Previous 1 2 3 4 5 6 Next >
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
From Pacira BioSciences
Via GlobeNewswire
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
Investors should take notice ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
From Pacira BioSciences
Via GlobeNewswire
Earnings Preview: Pacira BioSciences
Via Benzinga
Analyst Expectations for Pacira BioSciences's Future
Via Benzinga
4 Analysts Have This to Say About Pacira BioSciences
Via Benzinga
Pacira BioSciences Reports Third Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
From Pacira BioSciences
Via GlobeNewswire
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
From Pacira BioSciences
Via GlobeNewswire
Analyst Ratings for Pacira BioSciences
Via Benzinga
Looking Into Pacira BioSciences's Return On Capital Employed
Via Benzinga
Recap: Pacira BioSciences Q1 Earnings
Via Benzinga
American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces Leadership Succession Plan
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
From Pacira BioSciences
Via GlobeNewswire
What 6 Analyst Ratings Have To Say About Pacira BioSciences
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 225 companies set new 52-week lows. 
Via Benzinga
Pacira BioSciences Reports Second Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Why Pacira BioSciences Shares Are Trading Lower Today
Pacira BioSciences Inc (NASDAQ: PCRX) reported Q1 sales of $160.3 million compared to $158.0 million a year ago and the  
Via Benzinga
Pacira BioSciences Reports First Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.